Business Context and Reporting Period
This Form 8-K Current Report was filed by Omeros Corporation on May 12, 2023. The filing discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on personnel and governance matters.
Material Changes
- Board Expansion: The Board of Directors increased the number of directors to nine.
- New Appointment: Diana T. Perkinson, M.D., was appointed as a director effective immediately.
- Committee Assignment: Dr. Perkinson was appointed to the Board's Scientific Committee.
- Compensation: Dr. Perkinson was granted a stock option to purchase 30,000 shares of common stock pursuant to the non-employee director compensation policy.
Outlook, Risks, and Management Commentary
The filing provides a professional biography of Dr. Perkinson, highlighting her dual board certifications in nephrology and internal medicine, her experience as a physician since 1987, and her prior roles at the University of Washington and Swedish Hospital. The Company states that Dr. Perkinson has no direct or indirect material interest in any existing or proposed transactions requiring disclosure under Item 404(a) of Regulation S-K. No financial guidance, risk factors, or unusual items are discussed in this report.
Key Facts for Investor Verification
- Verify the total number of directors on the Board is now nine.
- Confirm the grant of 30,000 stock options to Dr. Perkinson and the associated vesting terms (not detailed in this text).
- Review Dr. Perkinson's background in nephrology to assess alignment with Omeros' therapeutic focus.
- Check for any subsequent filings regarding the expiration of Dr. Perkinson's initial term at the 2023 annual meeting.